Sava announced a USD 36 million Series B on 9 October 2026, led by Ascensia Diabetes Care. Imperial researchers Renato Circi and Rafaël Michali founded the London company to develop wearable glucose microsensors. The financing is accompanied by an Ascensia partnership supporting its planned European market entry. Sava's work centres on a sensing platform for diabetes care, combining research in miniature devices with the requirements of a medical product. The investment brings a corporate healthcare partner into the company's next stage. Its story links university-origin technology, specialist founders and a distribution relationship relevant to bringing the proposed product to users.
Sava raises USD 36m Series B
Ascensia Diabetes Care leads funding and a European distribution partnership

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


